ArticleCureus2026
Ultra-Rapid Cycling Bipolar Disorder: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultra-rapid cycling disorder, in which mood episodes shift over days rather than months, sits at one of the most difficult ends of the bipolar spectrum. It resists standard treatment, tends to worsen with antidepressants, and has very little long-term outcome data to guide clinical decisions. We report the case of a 51-year-old woman whose ultra-rapid cycling bipolar disorder was tracked for 130 weeks. She underwent trials of multiple mood stabilizers, five second-generation antipsychotics, and two courses of electroconvulsive therapy (ECT), none of which produced sustained remission. Clozapine brought the most meaningful improvement seen across the entire treatment period but had to be stopped because of sialorrhea and weight gain. The patient described the sialorrhea as feeling like she was drowning in her own saliva, a symptom that, while pharmacologically manageable, was not addressed in time to preserve the treatment. She was subsequently transitioned to long-acting injectable aripiprazole, primarily to address adherence. Ultra-rapid cycling bipolar disorder is genuinely hard to treat, and this case shows what that looks like in practice. Sustained remission may require earlier procedural intervention, more aggressive management of comorbidities, and a willingness to consider agents, including clozapine, that are often reserved as a last resort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.